J Am Coll Cardiol. [Michael looks at Neri]  [Connie and Vincent enter] 

Evaluating time in therapeutic range for hemodialysis patients taking warfarin.
The nephrologist is not eligible for the professional fee.For the period starting from January 1st, 2015 and ending on November 26th, 2016, we identified 341 patients in Institution A and 300 patients in Institution B who were undergoing hemodialysis for at least 3 months. 2 patients were added to the final TTR analysis, because they were on warfarin, but stopped during study period with duration of non-hospitalized INR testing ≥140 day. 2009;20:2223–33.Wizemann V, Tong L, Satayathum S, et al. INR values during hospital admissions lasting more than 2 days were excluded as were any INRs obtained within the first week post discharge.

Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. 1991;84(2):527–39.Camm AJ, Kirchhof P, Lip GY, Schotten U, et al.

It is important to note that this analysis is based on laboratory and professional fees specific to the Province of Quebec, Canada, which vary somewhat among Canadian provinces and more so across other countries.Our study demonstrates a nearly equal mean TTR among chronic hemodialysis patients receiving warfarin, whether managed by specialized anticoagulation clinic or by nephrologists. 2011;12:46.Genovesi S, Rossi E, Galleni M, et al.

[to Zasa] 

N Engl J Med. Vincent Mancini. View Al Neri’s profile on LinkedIn, the world's largest professional community.

Brancaccio D, Neri L, Bellocchio F, et al. A historical cohort study.

Warfarin in CKD patients with atrial.

Nephrol Dial Transplant. 20 patients were included in the final TTR analysis.

Cardiovascular disease in chronic kidney disease. You can also search for this author in CAS Article PubMed Google Scholar 10. Am J Nephrol.

[delirious]  In Institution A: 57 out of 341 patients on chronic hemodialysis had a documented history of atrial fibrillation.

The following additional data were collected from dialysis charts and/or electronic medical records: demographics (age and gender), CHADS2 score, total duration on hemodialysis, relevant comorbidities (congestive heart failure, coronary artery disease, hypertension, type 2 diabetes mellitus, cerebrovascular accidents, valvular atrial fibrillation), medication use (antiplatelet agents, NSAIDs, total duration of out-patient antibiotic use), and total number of days of hospitalization during the study period.The end points of the study were; 1) the mean TTR, based on the Rosendaal method, 2) the proportion of patients achieving TTR ≥ 60%, based on the Rosendaal method, 3) mean frequency of INR testing.The study cohort was stratified into two groups, Nephrologist-led management (Institution A) and Anticoagulation clinic-led management (Institution B).

Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. Li S, Chen X, Li Q, et al.

30 patients were included in the final TTR analysis. N Engl J Med.

In Institution A, 57 patients (16.7%) had documented history of atrial fibrillation, of whom 21 (36.8%) were on warfarin at the end of the study period.

[to Mary] 

Lancet. [Vincent bites Zasa's ear and Zasa is taken out of the office] 

Search

In Institution B, 18% of hemodialysis patients had atrial fibrillation, and 55.5% were on warfarin.